IMTX

Immatics N.V. Ordinary Shares (IMTX)

About Immatics N.V. Ordinary Shares (IMTX)

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

Details

Daily high

$9.66

Daily low

$9.22

Price at open

$9.24

52 Week High

$13.77

52 Week Low

$7.15

Market cap

957.9M

Dividend yield

0.00%

Volume

772,727

Avg. volume

723,831

P/E ratio

-10.33

Immatics N.V. Ordinary Shares News